Stock Taper 
AIDX
$0.47
▼ DOWN 1.36% (-0.01)
KEY STATISTICS
Market Cap$5.70 M
52w High$50.00
52w Low$0.40
Dividend Yield—
Frequency—
P/E-0.88
Volume28.82K
Shares Out.12.25M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Jonathan Cohen
COMPENSATION 2026
Salary$250,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$75,499
Total$325,499
ABOUT
SECTOR
Healthcare
WENT PUBLIC
February 19, 2026
METHOD OF GOING PUBLIC
Direct Listing
FULL TIME EMPLOYEES
14
PRICE TARGET
Target High$5.00
Target Low$5.00
Target Median$5.00
Target Consensus$5.00
PRICE
$0.47 ▼ DOWN 1.36% (−$0.01)About 20/20 Biolabs Inc.
https://2020biolabs.com ↗20/20 GeneSystems, Inc. is a Gaithersburg-based clinical lab specializing in multi-cancer early detection, viral testing, and supporting diagnostic innovation through shared labs and SaaS solutions.
INDUSTRY
Medical - Care Facilities
A PRODUCT 20/20 BIOLABS INC. IS KNOWN FOR
OneTest™ for Longevity
20/20 BioLabs' AI-driven blood test analyzes inflammatory biomarkers to assess chronic disease risk and offer personalized healthy aging recommendations, marking its expansion from cancer detection into preventative health and longevity.
ETFS HOLDING THIS STOCK
ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
RATINGS SNAPSHOT
Overall rating: C
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2
INSIDER TRADES
★
OFFICER: CHIEF FINANCIAL OFFICER
Bergman Alan B.
Purchase · 100.0K shares
2026-04-02
★
OFFICER: CHIEF OPERATING OFFICER
Zhou Jiming
Purchase · 150.0K shares
2026-04-02
★
DIRECTOR, 10 PERCENT OWNER, OFFICER: CHIEF EXECUTIVE OFFICER
Cohen Jonathan M
Purchase · 352.9K shares
2026-03-03
★
DIRECTOR
Rollins John Woodson
Sale · 13.0K shares
2026-02-19